FedQuery

The Univeristy Of Texas M.D. Anderson Cancer Center

UEI S3GMKS8ELA16 · TX · SAM.gov record ↗

$13.5M
FY2025 obligations
31
Contract awards
Aug 9, 2009
First action
Jun 29, 2026
Latest action

Obligations by agency

  • Department Of Health And Human Services$13.2M
  • Department Of Veterans Affairs$349K

Obligations by NAICS

Monthly obligations

Oct 24
Nov 24
Dec 24
Jan 25
Feb 25
Mar 25
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Sep 25
Nov 25
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Jun 26

Contracts ending within 18 months (recompete watch)

  • 75N98025F00003 ↗$123K

    V105: NON-HUMAN PRIMATE ACQUISITION

    Ends
    Sep 17, 2026
    Started
    Sep 18, 2025
    Agency
    National Institutes Of Health
    NAICS
    112990
  • 75N91023F00002 ↗$0

    TO TITLE: TARGETING DKK1 WITH A DNA VACCINE TO PREVENT DEVELOPMENT OF MULTIPLE MYELOMA BASE IDIQ TITLE: PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINTS BIOMARKERS

    Ends
    Oct 24, 2026
    Started
    Jun 25, 2023
    Agency
    National Institutes Of Health
    NAICS
    541714
  • 75N91024F00002 ↗$0

    TIME-RESTRICTED FEEDING FOR PANCREATIC CANCER PREVENTION

    Ends
    Dec 18, 2026
    Started
    Sep 19, 2024
    Agency
    National Institutes Of Health
    NAICS
    541714
  • 75N91023F00001 ↗$0

    TO TITLE: FURTHER DEVELOPMENT OF IPSC-BASED VACCINE FOR COLON CANCER PREVENTION BASE IDIQ TITLE: PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS

    Ends
    Dec 24, 2026
    Started
    Jul 25, 2023
    Agency
    National Institutes Of Health
    NAICS
    541714
  • 75N91023F00003 ↗$679K

    BASE IDIQ TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY & INTERMEDIATE BIOMARKERS TARGETING THE A2B ADENOSINE RECEPTOR FOR IMMUNOPREVENTION OF PANCREATIC CANCER

    Ends
    Mar 13, 2027
    Started
    Sep 14, 2023
    Agency
    National Institutes Of Health
    NAICS
    541714
  • 75N91025F00001 ↗$692K

    PROJECT TITLE: LOW-DOSE ERLOTINIB AND MESALAMINE FOR PREVENTION OF COLITIS-ASSOCIATED COLORECTAL CANCER (CAC)

    Ends
    Mar 23, 2027
    Started
    Sep 24, 2025
    Agency
    National Institutes Of Health
    NAICS
    541714
  • 75N91022F00001 ↗$0

    PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS TASK ORDER TITLE: TARGETING THE PARP PATHWAY FOR THE PREVENTION OF BREAST CANCER (2022 E-01)

    Ends
    May 30, 2027
    Started
    May 31, 2022
    Agency
    National Institutes Of Health
    NAICS
    541714
  • 36C24524P0903 ↗$388K

    MOD TO INCORPORATE 852.222-71 INTO THE CONTRACT PER ACQUISITION POLICY FLASH! 25-06.

    Ends
    Sep 28, 2027
    Started
    Sep 29, 2024
    Agency
    Department Of Veterans Affairs
    NAICS
    541990

Largest awards

  • 75R60219C00004 ↗$8.6M

    NATIONAL CORD BLOOD INVENTORY

    Ends
    Sep 2, 2035
    Started
    Sep 26, 2019
    Agency
    Health Resources And Services Administration
    NAICS
    621991
  • 75N97021C00001 ↗$2.0M

    OPERATION AND MAINTENANCE OF THE CHIMPANZEE CARE CENTER (CCC)

    Ends
    Jul 30, 2026
    Started
    Nov 30, 2020
    Agency
    National Institutes Of Health
    NAICS
    541940
  • 75F40125C00075 ↗$1.2M

    BAA-MD ANDERSON-STATISTICAL DESIGNS AND CONSIDERATIONS FOR DOSE OPTIMIZATION FY25C1FP6

    Ends
    Sep 28, 2028
    Started
    Sep 15, 2025
    Agency
    Food And Drug Administration
    NAICS
    541714
  • 75N91025F00001 ↗$692K

    PROJECT TITLE: LOW-DOSE ERLOTINIB AND MESALAMINE FOR PREVENTION OF COLITIS-ASSOCIATED COLORECTAL CANCER (CAC)

    Ends
    Mar 23, 2027
    Started
    Sep 24, 2025
    Agency
    National Institutes Of Health
    NAICS
    541714
  • 75N91023F00003 ↗$679K

    BASE IDIQ TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY & INTERMEDIATE BIOMARKERS TARGETING THE A2B ADENOSINE RECEPTOR FOR IMMUNOPREVENTION OF PANCREATIC CANCER

    Ends
    Mar 13, 2027
    Started
    Sep 14, 2023
    Agency
    National Institutes Of Health
    NAICS
    541714
  • 36C24524P0903 ↗$388K

    MOD TO INCORPORATE 852.222-71 INTO THE CONTRACT PER ACQUISITION POLICY FLASH! 25-06.

    Ends
    Sep 28, 2027
    Started
    Sep 29, 2024
    Agency
    Department Of Veterans Affairs
    NAICS
    541990
  • 75N98025F00003 ↗$123K

    V105: NON-HUMAN PRIMATE ACQUISITION

    Ends
    Sep 17, 2026
    Started
    Sep 18, 2025
    Agency
    National Institutes Of Health
    NAICS
    112990
  • 75N98025F00002 ↗$115K

    PER DIEM AND TESTING COST FOR THE NIAID AOTUS NHP COLONY

    Ends
    Jul 30, 2025
    Started
    Jul 31, 2024
    Agency
    National Institutes Of Health
    NAICS
    112990
  • 75N98025F00001 ↗$41K

    SQUIRREL MONKEY, BOLIVIAN, MIXED GENDER, SPF, IAW CONTRACT SOW AND RFQ N73

    Ends
    Jul 30, 2025
    Started
    Jul 31, 2024
    Agency
    National Institutes Of Health
    NAICS
    112990
  • 36C25726P0378 ↗$3K

    RATIFICATION FOR CALIBRATION SERVICES

    Ends
    May 14, 2026
    Started
    Oct 3, 2024
    Agency
    Department Of Veterans Affairs
    NAICS
    811210
  • 75N98021D00018 ↗$0

    NON-HUMAN PRIMATE ACQUISITION, TESTING, TRANSPORTATION AND HOUSING

    Ends
    —
    Started
    Jul 19, 2021
    Agency
    National Institutes Of Health
    NAICS
    112990
  • 75N91022F00002 ↗$0

    PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINTS BIOMARKERS TASK ORDER TITLE: TARGETING STAT3 TO PREVENT NON-SMALL CELL LUNG CANCER (NSCLC) IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

    Ends
    Jun 13, 2026
    Started
    Sep 14, 2022
    Agency
    National Institutes Of Health
    NAICS
    541714
  • 75N91023F00002 ↗$0

    TO TITLE: TARGETING DKK1 WITH A DNA VACCINE TO PREVENT DEVELOPMENT OF MULTIPLE MYELOMA BASE IDIQ TITLE: PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINTS BIOMARKERS

    Ends
    Oct 24, 2026
    Started
    Jun 25, 2023
    Agency
    National Institutes Of Health
    NAICS
    541714
  • 75N91024F00002 ↗$0

    TIME-RESTRICTED FEEDING FOR PANCREATIC CANCER PREVENTION

    Ends
    Dec 18, 2026
    Started
    Sep 19, 2024
    Agency
    National Institutes Of Health
    NAICS
    541714
  • 75N91023F00001 ↗$0

    TO TITLE: FURTHER DEVELOPMENT OF IPSC-BASED VACCINE FOR COLON CANCER PREVENTION BASE IDIQ TITLE: PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS

    Ends
    Dec 24, 2026
    Started
    Jul 25, 2023
    Agency
    National Institutes Of Health
    NAICS
    541714
  • 75N91022F00001 ↗$0

    PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS TASK ORDER TITLE: TARGETING THE PARP PATHWAY FOR THE PREVENTION OF BREAST CANCER (2022 E-01)

    Ends
    May 30, 2027
    Started
    May 31, 2022
    Agency
    National Institutes Of Health
    NAICS
    541714
  • 75N91019D00021 ↗$0

    PRECLINICAL EFFICACY AND INTERMEDIATE BIOMARKERS

    Ends
    —
    Started
    Jan 24, 2019
    Agency
    National Institutes Of Health
    NAICS
    541714
  • 75N91024D00004 ↗$0

    PRECLINICAL EFFICACY & INTERMEDIATE ENDPOINT BIOMARKERS IDIQ CONTRACT IN SUPPORT OF THE PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM

    Ends
    —
    Started
    Jan 24, 2024
    Agency
    National Institutes Of Health
    NAICS
    541714
  • HHSN268200900039C ↗$0

    CLOSEOUT MODIFICATION

    Ends
    Sep 12, 2017
    Started
    Aug 9, 2009
    Agency
    National Institutes Of Health
    NAICS
    541711
  • HHSN26100008 ↗$-598

    ALTERNATIVE DOSING OF EXEMESTANE IN POSTMENOPAUSAL WOMEN WITH STAGE 0-II ER-POSITIVE BREAST CANCER: A RANDOMIZED PRESURGICAL TRIAL

    Ends
    Jul 30, 2022
    Started
    Jul 31, 2015
    Agency
    National Institutes Of Health
    NAICS
    541712
  • 75N91020F00001 ↗$-3K

    BASE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY & INTERMEDIATE BIOMARKERS TASK ORDER: TARGETING STAT3 TO PREVENT HEPATOCELLULAR CARCINOMA (HCC) ASSOCIATED WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH)

    Ends
    May 30, 2025
    Started
    May 31, 2020
    Agency
    National Institutes Of Health
    NAICS
    541714
  • 75N91021F00002 ↗$-3K

    BASE CONTRACT TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY & INTERMEDIATE BIOMARKERS TASK ORDER TITLE: TARGETING STAT3 TO PREVENT COLORECTAL CANCER SECONDARY TO INFLAMMATORY BOWEL DISEASE

    Ends
    Mar 14, 2025
    Started
    Sep 15, 2021
    Agency
    National Institutes Of Health
    NAICS
    541714
  • 75N91021F00003 ↗$-3K

    BASE IDIQ TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY & INTERMEDIATE BIOMARKERS TASK ORDER TITLE: EVALUATION OF REAL-TIME METABOLIC IMAGING BIOMARKERS FOR DETECTION OF PANCREATIC PREMALIGNANT LESIONS

    Ends
    Mar 14, 2025
    Started
    Sep 15, 2021
    Agency
    National Institutes Of Health
    NAICS
    541714
  • HHSN26100012 ↗$-17K

    TOPICAL BEXAROTENE IN WOMEN AT HIGH RISK FOR BREAST CANCER

    Ends
    Apr 29, 2022
    Started
    Aug 31, 2017
    Agency
    National Institutes Of Health
    NAICS
    541712
  • 75F40123P00335 ↗$-21K

    THE PURPOSE OF THIS MODIFICATION IS TO MODIFY THE SUBJECT CONTRACT TO EXTEND THE CURRENT CONTRACT TO 12/31/2024.

    Ends
    Feb 27, 2025
    Started
    Aug 30, 2023
    Agency
    Food And Drug Administration
    NAICS
    541720